201 related articles for article (PubMed ID: 32362932)
1. Manipulating angiotensin metabolism with angiotensin converting enzyme 2 (ACE2) in heart failure.
Patel VB; Putko B; Wang Z; Zhong JC; Oudit GY
Drug Discov Today Ther Strateg; 2012; 9(4):e141-e148. PubMed ID: 32362932
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy.
Oudit GY; Penninger JM
Curr Heart Fail Rep; 2011 Sep; 8(3):176-83. PubMed ID: 21611889
[TBL] [Abstract][Full Text] [Related]
3. Role of ACE2 in diastolic and systolic heart failure.
Wang W; Bodiga S; Das SK; Lo J; Patel V; Oudit GY
Heart Fail Rev; 2012 Sep; 17(4-5):683-91. PubMed ID: 21638102
[TBL] [Abstract][Full Text] [Related]
4. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases.
Parajuli N; Ramprasath T; Patel VB; Wang W; Putko B; Mori J; Oudit GY
Can J Physiol Pharmacol; 2014 Jul; 92(7):558-65. PubMed ID: 24861775
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm.
Ferreira AJ; Hernández Prada JA; Ostrov DA; Raizada MK
Future Cardiol; 2008 Mar; 4(2):175-82. PubMed ID: 19804294
[TBL] [Abstract][Full Text] [Related]
6. [Regulation of angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis provides a new target for the treatment of cardiac remodeling and heart failure].
Yang L; Huang Y; He Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Nov; 31(11):1425-1428. PubMed ID: 31898578
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
8. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
9. [Role of ACE2-Ang (1-7)-Mas receptor axis in heart failure with preserved ejection fraction with hypertension].
Yu J; Wu Y; Zhang Y; Zhang L; Ma Q; Luo X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):738-746. PubMed ID: 30124209
[TBL] [Abstract][Full Text] [Related]
10. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.
Patel VB; Zhong JC; Grant MB; Oudit GY
Circ Res; 2016 Apr; 118(8):1313-26. PubMed ID: 27081112
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS.
Patel VB; Clarke N; Wang Z; Fan D; Parajuli N; Basu R; Putko B; Kassiri Z; Turner AJ; Oudit GY
J Mol Cell Cardiol; 2014 Jan; 66():167-76. PubMed ID: 24332999
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis.
Simões E Silva AC; Teixeira MM
Pharmacol Res; 2016 May; 107():154-162. PubMed ID: 26995300
[TBL] [Abstract][Full Text] [Related]
13. The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research.
Rodrigues Prestes TR; Rocha NP; Miranda AS; Teixeira AL; Simoes-E-Silva AC
Curr Drug Targets; 2017; 18(11):1301-1313. PubMed ID: 27469342
[TBL] [Abstract][Full Text] [Related]
14. Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System.
Nunes-Silva A; Rocha GC; Magalhaes DM; Vaz LN; Salviano de Faria MH; Simoes E Silva AC
Protein Pept Lett; 2017 Nov; 24(9):809-816. PubMed ID: 28758593
[TBL] [Abstract][Full Text] [Related]
15. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction.
Kassiri Z; Zhong J; Guo D; Basu R; Wang X; Liu PP; Scholey JW; Penninger JM; Oudit GY
Circ Heart Fail; 2009 Sep; 2(5):446-55. PubMed ID: 19808375
[TBL] [Abstract][Full Text] [Related]
16. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
17. N-Acetyl-Seryl-Asparyl-Lysyl-Proline regulates lung renin angiotensin system to inhibit epithelial-mesenchymal transition in silicotic mice.
Li S; Li Y; Zhang Y; Li S; Zhang M; Jin F; Wei Z; Yang Y; Gao X; Mao N; Ge X; Xu H; Yang F
Toxicol Appl Pharmacol; 2020 Dec; 408():115255. PubMed ID: 33007385
[TBL] [Abstract][Full Text] [Related]
18. ACE2: a new target for cardiovascular disease therapeutics.
Raizada MK; Ferreira AJ
J Cardiovasc Pharmacol; 2007 Aug; 50(2):112-9. PubMed ID: 17703127
[TBL] [Abstract][Full Text] [Related]
19. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.
Ferrario CM; Jessup J; Chappell MC; Averill DB; Brosnihan KB; Tallant EA; Diz DI; Gallagher PE
Circulation; 2005 May; 111(20):2605-10. PubMed ID: 15897343
[TBL] [Abstract][Full Text] [Related]
20. Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating K
Wang LP; Fan SJ; Li SM; Wang XJ; Gao JL; Yang XH
Pflugers Arch; 2016 Nov; 468(11-12):2041-2051. PubMed ID: 27592222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
